ARA-290 (Cibinetide): A Peptide for Nerve Repair

What is ARA-290?

ARA-290, also known as cibinetide, is a small synthetic peptide that grew out of research into erythropoietin (EPO), the hormone best known for stimulating red blood cell production. Scientists noticed that EPO also carries a separate, tissue-protective signal, and they set out to isolate that repair-related activity from the blood-building effect. ARA-290 is the result: a short peptide designed to engage tissue-protective signaling without raising red blood cell counts.

This places ARA-290 in a more specific niche than a general 'recovery' compound. It is being explored as a way to support nerve and tissue repair through a defined biological pathway, and most of its human research has centered on one particular problem: small fiber neuropathy, a form of nerve damage that affects the tiny fibers responsible for pain and sensation.

How it is thought to work

ARA-290 is understood to act on what researchers call the innate repair receptor, a signaling complex involved in protecting tissue and calming local inflammation after injury. By engaging this pathway, the peptide is proposed to support the survival and regeneration of small nerve fibers and to dampen the inflammatory environment that can accompany nerve damage. Preclinical work showed this same activity reduced allodynia, a heightened pain response, in animal models of neuropathy, which is what motivated the move into human testing.

Much of the receptor-level detail comes from laboratory and mechanistic research, and a plausible mechanism is not the same as a proven clinical effect. For ARA-290, that mechanism has been carried into controlled human testing, which is where the evidence below becomes relevant.

The human trial evidence

The human evidence for ARA-290 is unusually concrete for a peptide of this kind, though it is still early and narrow. A 2012 randomized, double-blind pilot trial in sarcoidosis patients with small fiber neuropathy reported that ARA-290 was safe and was associated with improved neuropathic symptoms. This was a small study, but it was placebo-controlled, which gives its signal more weight than open-label or anecdotal reports.

A 2013 randomized controlled trial built on this, again in sarcoidosis-associated small nerve fiber loss. It replicated the symptom benefit and, importantly, added an objective measure: an increase in corneal nerve fiber density, meaning the trial documented a physical change in nerve fibers rather than relying on symptom reports alone. A larger 2017 multicentre randomized controlled trial, published in an ophthalmology journal, focused specifically on this objective endpoint and reported that cibinetide improved corneal nerve fiber abundance in the same patient population.

That 2017 study was registered as a phase 2, four-arm dose-ranging trial (NCT02039687) comparing 1, 4, and 8mg daily doses against placebo in 64 subjects, with corneal nerve fiber area as the primary endpoint. The trial registry record confirms what the publication reported: an objective, dose-related nerve-density signal alongside the symptom improvements.

The same tissue-protective mechanism has also been examined outside neuropathy. A separate phase 2 trial (NCT01933529) tested ARA-290 in 24 people with prediabetes or early type 2 diabetes, looking at glucose tolerance, insulin secretion, and inflammatory markers. This reflects the broader scientific interest in the innate repair receptor as an anti-inflammatory target, though the published nerve-fiber work remains the most developed line of evidence.

Taken together, these are genuine randomized human trials with both subjective and objective endpoints, more than most compounds in this space can claim. The scope is still narrow: the core results sit in one condition, small fiber neuropathy in sarcoidosis, and range from small pilots to a multicentre phase 2 trial rather than large definitive studies. The neuropathy work is where the evidence is strongest and most consistent.

What it is being explored for and who it may suit

Based on the existing evidence, ARA-290 is most directly relevant to small fiber neuropathy and nerve regeneration, where the controlled trials have shown both symptom and structural signals. Its tissue-protective, anti-inflammatory mechanism has prompted wider scientific curiosity, including the early metabolic work above, but the neuropathy trials remain the clearest picture of what it can do in people.

Whether ARA-290 is appropriate for a given person depends on their specific situation, diagnosis, and goals. That is a conversation for a qualified physician after a full assessment, not a decision to make from an article.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. ARA-290 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.